Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals reported strong financial results for the second quarter and first half of 2026, with significant increases in revenue, net income, and EPS. The company also completed the acquisition of Kezar Life Sciences, Inc. for $51.6 million in cash. Additionally, Aurinia continued its share repurchase program, buying back 2.5 million shares for $38.1 million during the quarter.

Aurinia Pharmaceuticals reported strong financial results for Q2 2026, with total revenue increasing 19% to $83.2 million and diluted earnings per share rising 75% to $0.28. Net product sales of LUPKYNIS grew 19% to $79.4 million. The company ended the quarter with $443.1 million in cash and investments and reiterated its 2026 revenue guidance of $315 million to $325 million. Aurinia also provided updates on its clinical pipeline, including the initiation of a Phase 4 study for LUPKYNIS and clinical development for Aritinercept in four indications.

Aurinia Pharmaceuticals Inc. held its annual general meeting of shareholders on June 3, 2026. Key outcomes included the election of five directors to serve until the 2027 annual general meeting, the approval of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and the approval of the company's executive compensation through a non-binding advisory vote. Voting results showed strong support for all proposals.

Aurinia Pharmaceuticals Inc. has completed its previously announced acquisition of Kezar Life Sciences, Inc. The tender offer, which expired on May 8, 2026, resulted in approximately 80.24% of Kezar's outstanding shares being tendered at a price of $6.955 in cash plus one contingent value right per share. Following the successful tender offer, the merger was finalized on May 11, 2026, with Kezar becoming a wholly owned subsidiary of Aurinia Pharma U.S., Inc.

Aurinia Pharmaceuticals announced a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a contingent value right, with the transaction expected to close in Q2 2026. The company also reported strong first-quarter 2026 financial results, with net product sales of LUPKYNIS increasing 23% to $73.6 million and total revenue growing 24.4% to $77.7 million. Net income significantly improved to $34.4 million, and cash flows from operating activities saw a substantial increase.

Aurinia Pharmaceuticals reported strong financial results for Q1 2026, with total revenue increasing 24% to $77.7 million and diluted EPS rising 56% to $0.25. Net product sales of LUPKYNIS grew 23% to $73.6 million. The company reiterated its full-year 2026 revenue and net product sales guidance and highlighted progress in its pipeline.